CommercialCoverageMedium impact
08.01.76d, Evinacumab-dgnb (Evkeeza®)
Independence Blue Cross·Cardiology, Endocrinology, Internal Medicine·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has updated their pharmacy policy for Evinacumab-dgnb (Evkeeza®), a specialty medication used to treat homozygous familial hypercholesterolemia. This is a fresh commercial policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this high-cost specialty drug.
Action Required
By October 1, 2025: Billing team should review the full policy document at the provided URL to understand specific changes to Evinacumab-dgnb coverage, prior authorization requirements, or billing procedures. Update any relevant prior auth workflows and inform providers treating patients with homozygous familial hypercholesterolemia of potential coverage changes.